Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q2

2784.TEDINET S100PL0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.33T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.29T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥10.2bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥9.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.0bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥11.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥10.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.33Tat 2022-09-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.33Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥852.3bnat 2022-09-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥481.9bnat 2022-09-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥492.0bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥169.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥168.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥179.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥176.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥169.1bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥36.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥20.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥15.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥2.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥29.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥34.62022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.12022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥33.022021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.72021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio36.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.9%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥245m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.18T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.17T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥8.3bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥23.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥842m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥14m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥124.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥123.8bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥305m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.35T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.33T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥15.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥10.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥182m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥7.9bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥7.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥22.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30−¥285m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥129.9bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥129.6bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥284m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.30T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.29T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥8.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 539
ItemContextValueUnit
Current liabilitiesCurrentQuarterInstant823365000000JPY
Provision for share based remuneration nclPrior1YearInstant－JPY
Provision for share based remuneration nclCurrentQuarterInstant36000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant－JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant44000000JPY
Provision for loss on anti monopoly act provisionsPrior1YearInstant3994000000JPY
Provision for loss on anti monopoly act provisionsCurrentQuarterInstant3994000000JPY
Net defined benefit liabilityPrior1YearInstant8075000000JPY
Net defined benefit liabilityCurrentQuarterInstant7990000000JPY
Other nclPrior1YearInstant17273000000JPY
Other nclCurrentQuarterInstant16856000000JPY
Noncurrent liabilitiesPrior1YearInstant29343000000JPY
Noncurrent liabilitiesCurrentQuarterInstant28923000000JPY
LiabilitiesPrior1YearInstant832156000000JPY
LiabilitiesCurrentQuarterInstant852289000000JPY
Capital stockPrior1YearInstant18454000000JPY
Capital stockCurrentQuarterInstant18454000000JPY
Capital surplusPrior1YearInstant101660000000JPY
Capital surplusCurrentQuarterInstant57720000000JPY
Retained earningsPrior1YearInstant352015000000JPY
Retained earningsCurrentQuarterInstant353548000000JPY
Treasury stockPrior1YearInstant-44625000000JPY
Treasury stockCurrentQuarterInstant-685000000JPY
Shareholders equityPrior1YearInstant427504000000JPY
Shareholders equityCurrentQuarterInstant429037000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant44760000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant53401000000JPY
Deferred gains or losses on hedgesPrior1YearInstant0JPY
Deferred gains or losses on hedgesCurrentQuarterInstant－JPY
Revaluation reserve for landPrior1YearInstant-3360000000JPY
Revaluation reserve for landCurrentQuarterInstant-3360000000JPY
Foreign currency translation adjustmentPrior1YearInstant200000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant351000000JPY
Remeasurements of defined benefit plansPrior1YearInstant2487000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant2208000000JPY
Valuation and translation adjustmentsPrior1YearInstant44088000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant52601000000JPY
Non controlling interestsPrior1YearInstant241000000JPY
Non controlling interestsCurrentQuarterInstant285000000JPY
Net assetsPrior1YearInstant471835000000JPY
Net assetsCurrentQuarterInstant481924000000JPY
Liabilities and net assetsPrior1YearInstant1303991000000JPY
Liabilities and net assetsCurrentQuarterInstant1334214000000JPY
Net salesPrior1YTDDuration1288706000000JPY
Net salesCurrentYTDDuration1332419000000JPY
Cost of salesPrior1YTDDuration1201370000000JPY
Cost of salesCurrentYTDDuration1241379000000JPY
Gross profitPrior1YTDDuration87336000000JPY
Gross profitCurrentYTDDuration91039000000JPY
Selling general and administrative expensesPrior1YTDDuration78218000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass